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This gender-independent detection of cell-free fetal DNA in maternal plasma using RASSF1A/-actin has curtained off  
a new dimension regarding its utility to predict the adverse pregnancy outcomes. Recent efforts have been directed  
at developing sequences from cell-free fetal DNA (cffDNA) as markers for pregnancy outcomes. The utility of  
cffDNA using the methylation-dependent DSCR3 and RASSF1A markers along with total cell-free DNA (cf-DNA)  
in maternal serum by HYP2 marker are useful in predicting adverse pregnancy outcomes.  Increased amount  
(>95th percentile) of cffDNA fraction in the second trimester is associated with preterm birth. Indigenously developed  
low-cost method of the gender-independent sequence markers from cffDNA was investigated and evaluated with  
the standardized commercial kits as predictive markers for adverse pregnancy outcomes. Our results indicated that 
indigenously developed method for detection of geneder-independent cffDNA can be applicable for screening test of 
adverse pregnancy outcome. 
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Cell-free DNA (cffDNA) in maternal plasma can be 
extracted using various commercially available kits1,2. 
Result of comparisons of various commercially 
available KITs has been published3. However, these 
kits are expensive4. There are few non-kit based 
methods cited in a few literatures where cffDNA has 
been extracted by the indigenous method without 
using any commercial kits5. Application of cffDNA 
could be used widely as a non-invasive prenatal test 
(NIPT) if the cost can be reduced for the developing 
countries like India.  
Locus specific differences in methylation between 
placenta trophoblast and maternal blood have been 
reported. This differential methylation pattern using 
various reported locus has been used to detect 
maternal DNA6. The promoter of RASSF1A is 
hypermethylated in trophoblast resulting in resistant 
to digestion by methylation sensitive restriction 
endonuclease HhaI, HpaII, Bstu1. On the contrary, 
the RASSF1A promoter is hypomethylated and 
sensitive to the digestion of the above restriction 
endonucleases in maternal blood7. Digestion of cell-
free DNA purified as stated above with the above 
restriction enzymes would quantify the cffDNA only 
on subsequent PCR amplification with specific 
primers8. Specific primers for amplification of β-
actin can be used as internal control. Additionally 
methylation sensitive promoters of ERG and serpin 
peptidase inhibitor, clade B (ovalbumin), member 5 
(SERPINB5) can also be used to detect the maternal 
DNA irrespective of gender of the fetal baby9. 
Preterm labour (PTL), intrauterine growth restriction 
(IUGR), intrauterine fetal death, fetal congenital 
anomalies, etc. often complicate a normal 
pregnancy. Hypertensive disorder in pregnancy is 
the leading cause of maternal death in developed 
countries and its incidence is increasing10,11. 
Detection of cell-free fetal DNA (cffDNA) in 
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maternal plasma opens the possibility of a non-
invasive probe into the health of the fetus. cffDNA 
has been utilized for prenatal diagnosis of several 
genetic diseases and screening for trisomy and fetal 
aneuploidy12. In recent years, an increased amount of 
cffDNA in maternal plasma has been reported in 
several studies in Preeclampsia (PE) and in few 
studies for IUGR and PTL13. 
The aim of the present study is toevaluate whether 
an elevated amount of cffDNA in maternal plasma is 
associated with adverse outcomes of pregnancy. The 
demographic variation of cffDNA in maternal 
plasma will also be tested. To test the hypothesis, we 
shall detect and quantify cffDNA in maternal plasma 
among pregnant women. We shall compare the 
amount of cffDNA obtained among pregnant women 
having adverse outcomes with that of women 
without any complications. In addition, selected 
women will undergo follow up till delivery to 
determine the outcome. 
 
Materials and Methods: 
Considering the constraint of logistic and time we 
hereby proposed to screen 100 pregnant women with 
and without pregnancy related complications in this 
prospective study, and follow them till delivery. 
Every participant underwent structured 
questionnaire, clinical examination, biochemical 
investigations. Structure questionnaire included age, 
parity (number of children born), previous history of 
PE / IUGR/ PTL/ preterm birth, family history of 
PE/IUGR / PTL, time interval between pregnancies, 
gestational age at entry and gestational age at 
delivery. Clinical examination includes Body mass 
index (BMI), Blood pressure, Proteinuria, 
Biochemical Investigations, Blood profile 
(hemoglobin platelet count), Liver function test 
(LFT), Urea, creatinine (Kidney function), Uric acid, 
and other antenatal routine investigations. About  
5 mL of peripheral blood was drawn into an EDTA 
tube. Plasma has been separated by centrifugation at 
1600 × g at 4°C for 10 min, and re-centrifuged once 
again at 16000 × g at 4°C for 10 min. The upper 
layer of the plasma has been distributed into 1.5 mL 
tubes (300 µL in each tube). About 350 µL plasma 
either immediately would be used for estimation of 
cell-free DNA or to be stored at −80°C for future 
use. Comparisons of various methods for total yield 
were made. These methods consist of (a) Triton X-
100/ Heat/ Phenol Chloroform method (THP) 
method after SDS and proteinase K lysis, (b) 
Salting-out protein precipitation method with 6 M 
sodium chloride, (c) Guanidium isothiocynate-based 
DNA extraction method and (d) commercial 
available kits. In our initial experiments, we have 
used methods (a), (b), (c) and (d). Our initial 
observation (unpublished) indicates that guanidium 
isothiocynate -based DNA extraction was convenient 
and the yield was higher. DNA has been quantified 
using “Qubit Fluorimeter” and Qubit ds DNA HS 
assay Kit (Cat no. Q32851). We have also compared 
the quality and yield of cell-free DNA isolated from 
the non-kit methods and that from isolated using Kit 
in the initial phase. The use of various KIT and 
modified methods as described above has been 
standardized for recovering consistence quantity 
cell-free fetal DNA. The concentration of cffDNA 
was measured in Genomic Equivalent (GE/µL). The 
study was approved by the Institutional Ethics 
Committee (No.F-24/ Pr/ COMJNMH/ 
IEC/16/1210).  
 
Non-Kits Based Methods for isolation of cffDNA 
Salting-out protein precipitation method 
Maternal plasma of about 350 μL is mixed with 
equal volume of buffer solution (0.45 M NaCl, 10 
mM TrisHCl, 25 mM EDTA in a 1.5 mL Eppendorf 
tube, 5 μL Proteinase K (20 mg/mL) and 15 μL SDS 
solution are added and kept at 56°C for 3 h. After 
that 300 μL NaCl 6 M is added and centrifuged at 
10000 rpm/min for 15 min14. The supernatant is then 
transferred to a 5 mL plastic graduated cylinder 
centrifuge tube and twice the volume of absolute 
ethanol is added. Transfer the supernatant to a fresh 
tube and kept at −80°C for 20 min, and re-
centrifuged at 12000 rpm/min for 10 min. Discard 
the supernatant and precipitated DNA using 70% 
ethanol and then dry it in air closet at 65°C for 3 
min15. Finally, dissolve it in 20 μL Tris-EDTA (TE) 
buffer solution and kept it at 4°C. 
 
Guanidiumisothiocynate-based DNA extraction method 
Maternal plasma of about 200 μL is added with  
500 μL of alanine aminotransferase (ALT/GPT) 
reagent (6 M guanidine thiocyanate dissolved in  
50 mM Tris and mixed with an equal volume Phenol 
buffered in Tris) in a tube, and mixed. The solution is 
kept in a boiling water bath for 15 min16. The tube is 
spin for 5 sec and add 250 μL chloroform-
isoamaylalcohol (24:1 by volume),centrifuge at 14000 
rpm/min for 10 min and the 450 μL liquid phase is 
transferred in a fresh tube, mixed with 500 μL 100% 
SAHA et al.: DEMOGRAPHIC VARIATION OF GENDER INDEPENDENT SEQUENCES IN cffDNA 
 
187
isopropanol and 25 mM kept at −20°C overnight. It is 
centrifuged at 14000 rpm/min for 15 min next day, 
remove the supernatant was removed without 
disturbing the nucleic acid pellet. Traces of GPT 
reagent are to be removed by the addition of ice-cold 
500 μL 70% ethanol. Then inverse the tube twice and 
again centrifuge it at 14000 rpm/ min for 5 min. 
Ethanol was removed and the pellet was stored. 
 
Triton X-100/Heat/ Phenol Chloroform method (THP) method 
Maternal plasma of about 500 μL is mixed with  
5 μL Triton X-100 solution and heated at 98°C for  
5 min. Keep the sample over ice for 5 min,  
mixed with equal volume of phenol, chloroform, 
isoamayl alcohol (25:24:1, v:v:v) and centrifuged at 
14000 rpm/min for 10 min. The aqueous phase is 
transferred to a separate tube, allowed to precipitate 
overnight by 1/10 volume of 3 M sodium  
oxalo-acetate (NaOAc) and 2.5 times volume of 
100% ethanol. DNA pellets are washed with  
ethanol, air dried and re-suspended in 50 μL  
double-distilled water17. 
Locus specific differences in methylation between 
placenta topoblast and maternal blood have been 
reported18,19. We have utilized this differential 
methylation pattern using various reported locus and 
has been used to detect maternal DNA20. The 
promoter of RASSF1A is hypermethylated in 
trophoblast resulting in resistant to digestion by 
methylation sensitive restriction endonuclease 
HhaI, HpaII, Bstu1. On the contrary, the RASSF1A 
promoter is hypomethylated and sensitive to the 
digestion of the above restriction endonucleases. 
Thus digestion of cell-free DNA purified as stated 
above will be digested with the above restriction 
enzymes. Subsequent PCR amplification with 
specific primers around the promoter would detect 
the quantity of fetal DNA21.Specific primers for 
amplification of β-actin will be used for internal 
control. Additionally, mehylation sensitive 
promoters of ERG and serpin peptidase inhibitor, 
clade B (ovalbumin), member 5 (SERPINB5) will 
also be used to detect the maternal DNA irrespective 
of the gender of the fetal baby as described22,23. PCR 
product will be detected by real time PCR using 
SYBER green. 
 
Different available commercial kits 
Three spin column-based kits for isolation of 
cffDNA [DNA Blood Mini Kit (DBM), DSP Virus 
Kit (DSP) and Circulating Nucleic Acid (CNA) Kit 
are available. Presently it is very difficult to find out 
the best available kit for isolation of cffDNA from 
plasma in an accurate manner24. 
 
Investigation of Gender Independent Sequences in cffDNA 
Quantitative changes of cell-free fetal cffDNA in 
maternal plasma as an indicator for impending 
preeclampsia have been reported in different studies, 
using real-time quantitative PCR for the male-
specific SRY or DYS 14 loci25. Recent efforts have 
been directed at developing gender-independent 
sequences from cffDNA as markers for preeclampsia 
Several studies showed the utility of cffDNA using 
the methylation dependent DSCR3 and RASSF1A 
markers along with total cell-free DNA (cf-DNA) in 
maternal serum by HYP2 markers either alone or in 
combination with biochemical marker like PAPP-A26 
are potentially effective in early prediction of 
preeclampsia. The higher concentration of cffDNA, 
cfDNA along with soluble endoglin in maternal 
serum are found in preeclampsia and particularly 
cffDNA and cfDNA are twofold higher in  
severe preeclampsia group than the mild group27. 
Variation of the standardized protocol is a major 
issue for meta analysis reports to opine about the 
efficacy of cffDNA28. However, no such studies 
have been performed in the Indian context and it is 
necessary to investigate and evaluate the gender-
independent sequence markers from cffDNA as 
predictive markers for preeclampsia in pregnant 
women in India. 
 
Statistical analysis 
Results were expressed as mean SE (standard 
error). All statistical analysis was performed by one-
way analysis of variance (ANOVA) with bivariate 
correlation tests and Student’s ‘t’ test using the 
Statistical Package for Social Sciences, version 25 
(SPSS, Chicago, Illinois). A ‘P’ value of <0.05 was 
considered significant. 
 
Result 
We have found in our study that the concentration of 
cffDNA increases with age, gravida, BMI  
(Table 1). But there is a typical variation in 
corresponding with the gestational age. Though with 
the increase in gestational age, cffDNA concentrations 
increase but at term (after 37 weeks) it again decreases 
in the maternal serum. The rise of blood pressure 
increases cffDNA concentration in the maternal serum 
enormously particularly when blood pressure is more 
than 140/90 mm Hg. The concentration of cffDNA 
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depends on the birth weight of the baby also, as it 
increases when the birth weight of the baby is less than 
2500 g and when it is <1500 g there is an abrupt rise of 
cffDNA concentration. In our study we have observed 
in longitudinal follow up that out of 100 mothers, 12 
mothers delivered by preterm labour, 4 women 
developed preeclampsia and 18 women delivered low 
birth weight baby, out of whom two were severe low 
birth weight (<1500 g).  
A comparison of different methods of isolation of 
cffDNA was done by analysis. Descriptive analysis of 
cffDNA (Table 2) has revealed that the interquartile 
range of cffDNA in guanidine isothiocyanate was 
7.665 - 52.2 (GE/ µL) (95% CI for the median = 7.74 
- 44.07) and in commercial kit (QIAamp MinElute 
cffDNA mini kit (Qiagen), the interquartile range was 
8.32 - 49.56 (95% CI for the median = 8.12 – 56.76) 
and both are comparable (Table 2). 
 
Table 1 — Comparison of variation of cffDNA concentration#  
in different demographic, and baseline parameters (n=100) 
Parameters Number of Patients Concentration of cffDNA (GE/ µL)* 
Age (yrs)  
18-23 
>23-28 
>28-33 
>33 
 
35 
42 
15 
8 
 
7.74 ± 0.21 
7.92 ± 0.92 
9.44 ± 0.32  
14.56 ± 1.12 (< 0.001) 
Gravida 
Primi (1st) 
Second (2nd) 
Third (3rd) 
>3rd 
 
22 
59 
16 
3 
 
5.34 ± 0.34 
8.66± 0.42 
9.42 ± 0.48 
12.76 ± 1.24 (0.342) 
Gestational Age  
 20 week (at entry) 
<37 week (preterm) 
>37 week (term) 
100 
12 
88 
7.82± 0.28 
132 ± 3.28 (<0.001) 
14.32 ± 1.91 
Systolic blood pressure (mmHg) 
<120 
120-130 
>130-140 
>140 
 
67 
19 
10 
4 
 
6.53 ± 0.46 
8.40± 0.93 
24.68 ± 3.11 
546.78 ± 72.68 (<0.001) 
Diastolic blood pressure (mmHg) 
<80 
80-85 
>85-90 
>90 
 
72 
16 
9 
3 
7.43± 0.36 
8.20± 0.56 
26.43± 4.16 
692 ± 84.72 (<0.001) 
Community 
Tribal (Mandi,Tudu, Murmu) 
Others 
32 
68 
116.76 ± 2.25 (<0.001) 
7.34± 0.62 
Body Mass Index (BMI) 
18.5–24.9 
25.0–29.9 
30.0–34.9 
35.0–39.9 
38 
42 
17 
3 
7.82± 0.48 
7.96± 0.63 
32.76 ± 3.26 
287.64 ± 36.52 (<0.001) 
Birth Weight (gm) 
>2500  
2500 – 1500 
<1500 
82 
16 
2 
5.98± 0.53 
40.66 ± 2.41 
482.44 ± 39.72 (<0.001) 
*All statistical analysis was performed by one-way analysis of variance (ANOVA), ܲ values <0.05 were considered as statistically
significant 
#cffDNA extracted by guanidiumisothiocynate-based DNA extraction method where maternal plasma with alanine aminotransferase
(ALT/GPT) reagent (6 M guanidine thiocyanate dissolved in 50 mM Tris and mixed with an equal volume Phenol buffered in Tris) 
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Discussion 
In a recent study with 107 pregnant women having 
clinically established PE at their third trimester and 93 
normotensive pregnant women, it has been shown that 
total cell-free DNA, cell-free fetal DNA and soluble 
endoglin (sEng) increased significantly among 
women with PE29. It has also been observed that 
elevated total cell-free DNA and cffDNA were also 
significantly higher among women with preterm labor 
and adverse fetal outcome groups compared with the 
term and favorable outcome groups30. These three 
markers were almost equivalent about the area under 
the curve for predicting adverse fetal outcome in the 
severe PE group. No significant difference in levels of 
cffDNA was observed in the first trimester in women 
who subsequently develop preeclampsia31. One study 
suggested that pre-diabetes is associated with the 
feature of metabolic syndrome including BMI32. Our 
study showed that levels of cell-free total DNA being 
increased in tribal population compared with white 
women with increasing BMI33. Interestingly, total 
cell-free DNA in pregnant women is dependent on 
ethnicity. In a study Cell-free total DNA was higher 
in African American (median; 25-75%; 6.15; 0.14-
28.73; p = 0.02) and Hispanic (4.95; 0.20-26.82; 
p = 0.037) compared with white women (2.33; 0.03-
13.10). This result shows that cell-free DNA in 
maternal plasma may depend on ethnic background34. 
No systematic study has been carried out so far and 
requires further studies. In a study with 8 women with 
preeclampsia and 8 normotensive control with singlet 
on male pregnancy between 28 and 32 gestational 
weeks, it has been shown that cell-free fetal DNA. 
Concentrations were higher in early preeclamptic 
women than control subjects35, along with alteration of 
other novel markers (e.g. hepcidin, serum iron) as 
suggested in other study36.To determine relationship 
between maternal and fetal characteristics and 
pregnancy outcomes on fetal and maternal cell-free 
DNA in maternal plasma at 11-13 weeks gestation, it 
has been observed that cell-free DNA in maternal 
plasma was not significantly altered in pregnancies 
complicated by preeclampsia, early spontaneous 
preterm birth (SPB) delivery of small for gestational 
age (SGA) neonates. However, fetal cfDNA level has 
been related to maternal weight and uterine artery 
pulsatility index and maternal cfDNA increased with 
maternal weight. It cannot be ruled out that whether 
the cffDNA increased in the advanced stage of 
gestation37. 
There are several studies to show that cffDNA is 
increased in IUGR. An increase in cffDNA was 
observed for the cases with a growth-restricted fetusin 
comparison with the controls38. Quantification of 
cffDNA using SRY sequences in 64 male-bearing 
pregnant women with IUGR and 89 controls revealed 
a significant increase of cffDNA in women with 
IUGR compared with control39. Significantly higher 
cffDNA was detected in fetal growth restriction 
groups than in normal pregnancy40. 
Women having elevated cffDNA in mid-trimester 
are at risk of spontaneous preterm delivery41. Women 
with episodic preterm labor and higher concentration 
of cffDNA are at increased risk for preterm delivery42. 
 
Conclusion 
cffDNA concentration is variable in the maternal 
plasma in relation to the number of pregnancy, age of 
the mother, period of gestational age, ethnicity 
particularly in tribal population and BMI. 
Indigenously developed low-cost method for isolation 
and quantification of cffDNA to predict various 
adverse pregnancy outcomes is equally effective as 
commercially available kits. Qualitative analysis by 
the epigenetic approach to identify individual genetic 
components for particular condition is the future way.  
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Table 2 — Comparison between different methods of cffDNA isolation 
Variables  Salting out Guanidine Isothiocyanate Phenol/Chloroform QIA ampmin Elute ccfDNA mini kit (Qiagen) 
Sample size 10 70 10 10 
Lowest value 3.66 2.18 2.7600 1.19 
Highest value 156.12 619.36 262.46 676.46 
Median 12.21 29.98 17.42 32.34 
95% CI for the median 2.0907 - 6.1124 7.74- 44.07 5.56 - 8.94 8.12 - 56.76 
Interquartile range 2.5 - 17.5 7.665 - 52.2 3.56 - 16.82 8.32 - 49.56 
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